OneConnect Financial Technology Co., Ltd. (NYSE:OCFT) Q3 2024 Earnings Conference Call November 14, 2024 7:00 AM ET Company Participants Rick Chan - Head of IR Shen Chongfeng - Chairman and CEO Michael Lin - CFO Conference Call Participants Operator Ladies and gentlemen, thank you all for standing by and welcome to OneConnect's Third Quarter 2024 Earnings Call. Currently, participants are in a listen-only mode. We will be facilitating a question-and-answer session at the end of today's call. [Operator Instr ...

Pure Cycle Corporation (NASDAQ:PCYO) Q4 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mark Harding - President and Chief Executive Officer Dan Kozlowski - Board Member Conference Call Participants Elliot Knight - Knight Advisors Bill Miller - Private Investor John Rosenberg - Loughlin Water Partners Operator Greetings, and welcome to the Pure Cycle Corporation Year-End 2024 Earnings Call. At this time, all participants are on a listen-only mode, and a question-and-answer se ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - Chief Financial Officer & Company Secretary Lorianne Masuoka - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 20 ...

Financial Data and Key Metrics - For Q1 FY2025, the company did not record any product sales to pharmacy distributors due to the sale of Vyleesi's worldwide rights in December 2023 [4] - Gross product sales for Q1 FY2024 were $4.6 million, with net product revenue of $2.1 million [5] - Total operating expenses for Q1 FY2025 were $7.8 million, down from $8.2 million in the same period last year, primarily due to the elimination of Vyleesi selling expenses [5] - Net cash used in operations for Q1 FY2025 was $7 million, compared to $5.9 million in Q1 FY2024, mainly due to increased net loss [6] - Net loss for Q1 FY2025 was $7.8 million, up from $5.2 million in Q1 FY2024, primarily due to the elimination of Vyleesi net product revenue [7] - Cash and cash equivalents as of September 30, 2024, were $2.4 million, down from $9.5 million as of June 30, 2024 [8] Business Line Data and Key Metrics - The company is focusing its future investment and activities on its core obesity programs, while exploring strategic options for non-obesity programs [9] - The Phase 2 study BMT-801, evaluating the combination of bremelanotide and tirzepatide for obesity, is fully enrolled with top-line results expected in Q1 2025 [10][11] - The obesity and weight loss management portfolio includes novel Melanocortin-4 receptor peptide agonists and orally active MCR4 selective small molecule agonists, with IND-enabling activities and clinical studies planned for 2025 [12] - The Phase 2 study for PL8177, an orally selective MCR1 treatment for ulcerative colitis, is expected to have top-line data in Q1 2025 [14] Market Data and Key Metrics - The pharmacological treatment of obesity is in the early stages of a multiyear cycle of innovation, with a market value expected to exceed $100 billion annually [16] - The Melanocortin system plays a critical role in regulating stored energy and food intake, and Melanocortin-4 receptor agonists are expected to be an important part of future obesity treatment [16] Company Strategy and Industry Competition - The company is focusing its research and development efforts on MCR-4 obesity assets to drive substantial shareholder value [18] - The company is exploring multiple strategic options for its non-obesity programs, including out-licensing, engagement with investors, and potential business combinations [19] - The company believes its ocular assets, including the Phase 3 dry eye disease program and lead compounds in glaucoma and retinal diseases, have significant value and are worthy of continued investment [18] Management Commentary on Operating Environment and Future Outlook - The company is optimistic about its position in the obesity treatment market, with high interest in its Melanocortin-based therapeutics [44] - The company is actively engaging in business development discussions for its ulcerative colitis program, with significant interest from multiple large companies [21] Other Important Information - The company received a $2.5 million deferred payment in November 2024 from Cosette Pharmaceuticals related to the sale of Vyleesi, which is not included in the September 30, 2024, cash balance [8] Q&A Session Summary Question: Options for the ulcerative colitis program following data - The company is exploring typical partnering discussions with larger companies, with significant interest from multiple parties under CDA [21] Question: Success criteria for the BMT-801 study and next steps - The study aims to demonstrate increased weight loss by combining Melanocortin mechanism with incretin therapy, with additional focus on weight loss maintenance and lean muscle mass preservation [22][23][24][25][26][27][28] Question: Potential for MCR-4 long-acting peptide and oral small molecule approaches - The company views these approaches as having broad applicability, including weight loss maintenance, add-on therapy, and potential monotherapy for patients failing other treatments [29][30][31][32][33] Question: Position in the broader obesity market, particularly hypothalamic obesity - The company believes its Melanocortin approaches have broad applicability and are evaluating their role in hypothalamic obesity [34][35][36] Question: Mix of financial approaches for business development opportunities - The company is considering a variety of financial approaches, including out-licensing, corporate combinations, and project finance, depending on the specific program and potential return [38][39][40][41] Closing Remarks - The company is excited about its position in the obesity treatment market and the potential of its Melanocortin-based therapeutics to build substantial value [44][45]

Data Storage Corporation (NASDAQ:DTST) Q3 2024 Earnings Conference Call November 14, 2024 11:00 AM ET Company Participants Alexandra Schilt - Investor Relations Chuck Piluso - Chairman and CEO Chris Panagiotakos - Chief Financial Officer Conference Call Participants Matthew Galinko - Maxim Operator Greetings. And welcome to the Data Storage Corporation 2024 Fiscal Third Quarter Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the form ...

Cosan S.A. (NYSE:CSAN) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Nelson Gomes - Chief Executive Officer of Raízen Marcelo Martins - Chief Executive Officer Rodrigo Araujo - Chief Financial, Investor Relations Fernando Tinel - Head of IR & ESG Conference Call Participants Isabella Simonato - BofA Merrill Lynch Thiago Duarte - BTG Matheus Enfeldt - UBS Monique Greco - Itaú Bruno Amorim - Goldman Sachs Vicente Falanga - Bradesco Regis Cardoso - XP Operator Good morning, ...

Intuitive Machines, Inc. (NASDAQ:LUNR) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Stephen Zhang - Head, Investor Relations Steve Altemus - Chief Executive Officer Pete McGrath - Chief Financial Officer Conference Call Participants Austin Moeller - Canaccord Genuity Griffin Boss - B. Riley Securities Edison Yu - Deutsche Bank Andres Sheppard - Cantor Fitzgerald Josh Sullivan - Benchmark Company Suji DeSilva - Roth Capital Operator Ladies and gentlemen, thank you for st ...

Vislink Technologies, Inc. (NASDAQ:VISL) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mickey Miller - Chief Executive Officer Mike Bond - Chief Financial Officer Conference Call Participants Brian Kinstlinger - Alliance Global Partners Operator Good morning, and thank you for holding. Welcome to Vislink's Third Quarter 2024 Earnings Results Conference Call. My name is Chris, and I will be your operator for today's call. Joining us for today's presentation are the compan ...

BrightView Holdings, Inc. (NYSE:BV) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Chris Stoczko - Vice President of Finance and Investor Relations Dale Asplund - President and Chief Executive Officer Brett Urban - Chief Financial Officer Conference Call Participants Bob Labick - CJS Securities Tim Mulrooney - William Blair Greg Palm - Craig Hallum Capital Group Keen Fai Tong - Goldman Sachs Group Harold Antor - Jefferies Jeffrey Stevenson - Loop Capital Markets Operator ...

JD.com, Inc. (NASDAQ:JD) Q3 2024 Earnings Conference Call November 14, 2024 7:00 AM ET Company Participants Sean Zhang - Director of IR Sandy Xu - CEO Ian Shan - CFO Conference Call Participants Ronald Keung - Goldman Sachs Alicia Yap - Citigroup Kenneth Fong - UBS Thomas Chong - Jefferies Jialong Shi - Nomura Operator Hello and thank you for standing by for JD.com's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After management's prepared remarks, th ...